Send yourself the details of this trial and next steps
Please provide a valid email address.
Send yourself the details of this trial and next steps
Please provide a valid email address.
This doesn't look like a valid phone number. Please check.
Both First Name and Last Name are required. Please check.
Home»Leukemia» Looking for patients with relapsed or refractory chronic lymphocytic leukemia, acute lymphoblastic leukemia, and non-Hodgkin’s lymphoma to test a CAR T-cell treatment
Clinical Trial
Looking for patients with relapsed or refractory chronic lymphocytic leukemia, acute lymphoblastic leukemia, and non-Hodgkin’s lymphoma to test a CAR T-cell treatment
This phase 1/2 clinical trial will test the effectiveness of chimeric antigen receptor (CAR) T-cells in treating chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and non-Hodgkin’s lymphoma (NHL). The primary outcome will be measured by the response to treatment, overall survival, and the maximum tolerated dose. The trial is being conducted at Fred Hutch/University of Washington Cancer Consortium in Seattle, Washington.
The details
CAR T-cell therapy uses the patient’s own T-cells to fight B-cell blood cancers. The patient’s T-cells are collected and genetically engineered to express a receptor for the CD19 marker, a specific protein found on many cancerous B-cells. After the T-cells are injected back into the body, they are able to identify which cells are cancerous and initiate an attack against them.
The study will examine the highest dose of T-cells tolerated for 30 days, the movement of CAR-T cells throughout the body for 1 year, response rate for 1 year, overall survival and time until the disease progresses for up to 15 years.
Who are they looking for?
This trial is recruiting 189 patients with CD19 positive ALL, CLL, or NHL. Patients with CLL should be beyond first remission and have failed a purine analog and anti CD20 immunochemotherapy or not be eligible for the therapy. Patients with indolent or mantle cell NHL should be beyond first remission and have previously received chemoimmunotherapy (or be ineligible). Aggressive NHL patients should have relapsed or have residual disease after treatment. Those with ALL must have relapsed or refractory disease.
Ideal candidates will not require over 15 mg of corticosteroids a day or have an autoimmune disease requiring immunosuppressive therapy.
How will it work
Patients will undergo a laboratory procedure to collect T-cells that will be genetically engineered. On day 0 the CAR T-cells will be delivered back to the patients through an IV. Some patients may receive an additional infusion of the CAR-T cells 10-21 days after the first infusion.
